VB 892
Alternative Names: VB-8; VB-892Latest Information Update: 03 Mar 2026
At a glance
- Originator Evotec SE; Variant Bio
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
- Discontinued Unspecified
Most Recent Events
- 03 Mar 2026 Discontinued for Unspecified in Germany (unspecified route) prior to March 2026 (Variant Bio pipeline, March 2026)
- 03 Mar 2026 Discontinued for Unspecified in USA (unspecified route) prior to March 2026 (Variant Bio pipeline, March 2026)
- 03 Mar 2026 Preclinical trials in Idiopathic pulmonary fibrosis in Germany (unspecified route) prior to March 2026 (Variant Bio pipeline, March 2026)